CLINICAL SERVICES
Dr Ogilvie has extensive and long-standing experience in the investigation, diagnosis and management of all areas of internal medicine including:
GLP-1 AND GLP1/INCRETIN AGONISTS (e.g.. OZEMPIC AND MOUNJARO)
These were first developed for the treatment of type 2 diabetes and have had a transformative effect on its therapy, but are also very useful as weight loss agents.
Key Points
- They are highly effective in the treatment of high blood sugar in people with type 2 diabetes
- They induce substantial weight loss in people who are overweight or obese, whether or not they have type 2 diabetes
- Trials have shown that they reduce the risk of major adverse cardiovascular events in people with type 2 diabetes, and in obese people with atherosclerotic disease.
- They have been shown to reduce the risks of kidney disease in people with type 2 diabetes
- Obesity associated conditions (e.g. diabetes, metabolic dysfunction, heart failure, sleep apnoea, knee osteoarthritis) improve with their use
- Commonly used agents are given by injection but oral preparations are becoming available
- The therapeutic potential of these agents extends to a range of conditions such as cardiovascular disease, liver disease, neurodegenerative disease and substance abuse disorders, all of which are areas of current research
- Like all medicines they may have adverse effects – discuss with your doctor before use

